STIM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuronetics Inc (STIM) is not a strong buy for a beginner, long-term investor at this moment. While the company shows promising revenue growth, its negative net income, declining EPS, and gross margin, coupled with the lack of strong trading signals or positive news catalysts, suggest that it is better to hold off on investing for now.
The MACD is positive and expanding, indicating a bullish momentum. However, the RSI is neutral at 71.54, and moving averages are converging, showing no clear trend. The stock is trading near its R1 resistance level of 1.668, with a pre-market price of 1.6816, which suggests limited immediate upside potential.
The company reported an 85.73% YoY revenue increase in Q4 2025, and the announcement of a new CEO and collaboration with Compass Pathways could provide long-term growth opportunities.
Net income dropped by 43.47% YoY, EPS declined by 70.59%, and gross margin fell by 21.54%. The lack of recent news and neutral trading sentiment from hedge funds and insiders further weakens the case for immediate investment.
In Q4 2025, revenue increased significantly by 85.73% YoY to $41.78M. However, net income dropped to -$7.16M, EPS declined to -0.1, and gross margin fell to 51.95%, indicating profitability challenges.
Canaccord lowered the price target from $7 to $3 while maintaining a Buy rating. The firm highlighted operational cash flow positivity in Q2 and strategic developments such as the new CEO and a collaboration with Compass Pathways.
